About: Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review
Creator	Yang, Qian Wang, Min Pang, Junxiong Tan, Xuan Ang, Han Chen, Jacinta I-Pei Chin-Huat, Jason Chua, Yong Chuan Tan, Chorh Cook, Alex Ee, Pearleen Gutierrez, Ramona Gwee, Wei Hsu, Li Hui, Sharon Lewis, Ruth Ng, Xian Tan, Hao Teo, Yik Xiao, Sylvia Yap, Yap, Rowena Yi, Ian
source	Medline; PMC
abstract	Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.
has issue date	2020-02-26(xsd:dateTime)
bibo:doi	10.3390/jcm9030623
bibo:pmid	32110875
has license	cc-by
sha1sum (hex)	a73af08311f81abb995c85cf95358fedbbaec26a
schema:url	https://doi.org/10.3390/jcm9030623
resource representing a document's title	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review
has PubMed Central identifier	PMC7141113
has PubMed identifier	32110875
schema:publication	J Clin Med
resource representing a document's body	covid:a73af08311f81abb995c85cf95358fedbbaec26a#body_text
is schema:about of	named entity 'niclosamide' named entity 'observational study' named entity 'rRT-PCR' named entity 'cohort studies' named entity 'ClinicalTrials.gov' named entity 'genome' named entity 'BGI' named entity 'cell entry' named entity 'vaccines' named entity '2019-nCoV' named entity 'Systematic Review' named entity 'Clinical Medicine' named entity 'RNA' named entity 'vaccine' named entity 'RT-PCR' named entity 'SARS-CoV' named entity 'CDC' named entity 'adverse reactions' named entity 'Thailand' named entity 'virus' named entity 'systematic review' named entity 'Interferon' named entity 'MERS' named entity 'therapeutic strategies' named entity 'point of care testing' named entity 'Genome' named entity 'immune responses' named entity 'vaccine' named entity 'PCR' named entity '2019-nCoV' named entity 'clinical trials' named entity 'ribavirin' named entity 'coronaviruses' named entity 'clinical study' named entity 'SARS-CoV' named entity 'sputum' named entity 'PCR' named entity 'antibodies' named entity 'ribavirin' named entity 'virus' named entity '2019-nCoV' named entity 'SARS-related coronavirus' named entity 'antimalarial agent' named entity '2019-nCoV' named entity 'antiviral' named entity 'immunofluorescence assays' named entity 'upper respiratory' named entity 'SARS-CoV' named entity '28 days' named entity 'randomized study' named entity 'observational studies' named entity 'lopinavir/ritonavir' named entity 'RT-PCR' named entity 'gold standard' named entity 'United States' named entity 'virus' named entity 'SARS' named entity 'lung' named entity 'ribavirin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software